View Item 

Show simple item record

Women, opioid use and addiction
dc.contributor.authorGoetz, Teddy G.
dc.contributor.authorBecker, Jill B.
dc.contributor.authorMazure, Carolyn M.
dc.date.accessioned2021-02-04T21:50:04Z
dc.date.available2022-03-04 16:50:03en
dc.date.available2021-02-04T21:50:04Z
dc.date.issued2021-02
dc.identifier.citationGoetz, Teddy G.; Becker, Jill B.; Mazure, Carolyn M. (2021). "Women, opioid use and addiction." The FASEB Journal (2): n/a-n/a.
dc.identifier.issn0892-6638
dc.identifier.issn1530-6860
dc.identifier.urihttps://hdl.handle.net/2027.42/166190
dc.description.abstractIn the midst of the current coronavirus pandemic, the United States continues to struggle with an ongoing opioid epidemic, initially fueled by widespread prescribing of opioid medications during the 1990s. The primary reason for prescribing opioids is to treat pain. Women have more acute and chronic pain and have been prescribed these drugs in significantly greater numbers than men. Comparison of women and men with chronic pain also shows that women receive the majority of prescription opioids, and the use of these prescribed medications became the major pathway to misuse and addiction for women. Yet, recognition of the extent of women’s exposure to opioids and the attendant consequences has been limited. Attempts to stem the overall tide of the epidemic focused on reducing the availability of prescription opioids. However, as these medications became more difficult to obtain and treatment opportunities were limited, many turned to other synthetic opioids, such as heroin and fentanyl. Thus, the public health crisis of opioid addiction has endured. This paper highlights the importance of understanding differences among women and men in opioid use and its biological and psychosocial effects to advance the gender‐based treatment approaches and effective public health policy.
dc.publisherKaiser Family Foundation
dc.publisherWiley Periodicals, Inc.
dc.subject.othersex characteristics
dc.subject.otheropioid‐related disorders
dc.subject.otheraddiction medicine
dc.titleWomen, opioid use and addiction
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelBiology
dc.subject.hlbtoplevelScience
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166190/1/fsb221303.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166190/2/fsb221303_am.pdf
dc.identifier.doi10.1096/fj.202002125R
dc.identifier.doihttps://dx.doi.org/10.7302/113
dc.identifier.sourceThe FASEB Journal
dc.identifier.citedreferenceHerbeck DM, Jeter KE, Cousins SJ, et al. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone. J Addict Dis. 2016; 35 ( 4 ): 305 ‐ 314.
dc.identifier.citedreferenceChoo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone‐exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 2004; 75 ( 3 ): 253 ‐ 260.
dc.identifier.citedreferenceFitzsimons HE, Tuten M, Vaidya V, et al. Mood disorders affect drug treatment success of drug‐dependent pregnant women. J Subst Abuse Treat. 2007; 32 ( 1 ): 19 ‐ 25.
dc.identifier.citedreferenceBuchting FO, Emory KT, Kim Y, et al. Transgender use of cigarettes, cigars, and e‐cigarettes in a national study. Am J Prev Med. 2017; 53 ( 1 ): e1 ‐ e7.
dc.identifier.citedreferenceGonzalez CA, Gallego JD, Bockting WO. Demographic characteristics, components of sexuality and gender, and minority stress and their associations to excessive alcohol, cannabis, and illicit (noncannabis) drug use among a large sample of transgender people in the United States. J Prim Prev. 2017; 38 ( 4 ): 419 ‐ 445.
dc.identifier.citedreferenceBarger BT, Obedin‐Maliver J, Capriotti MR, et al. Characterization of substance use among underrepresented sexual and gender minority participants in The Population Research in Identity and Disparities for Equality (PRIDE) Study. Subst Abuse. 2020; 1 ‐ 12.
dc.identifier.citedreferenceHendricks ML, Testa RJ. A conceptual framework for clinical work with transgender and gender nonconforming clients: an adaptation of the Minority Stress Model. Prof Psychol Res Pract. 2012; 43 ( 5 ): 460 ‐ 467.
dc.identifier.citedreferenceKidd JD, Jackman KB, Wolff M, et al. Risk and protective factors for substance use among sexual and gender minority youth: a scoping review. Curr Addict Rep. 2018; 5 ( 2 ): 158 ‐ 173.
dc.identifier.citedreferenceSchuler MS, Rice CE, Evans‐Polce RJ, Collins RL. Disparities in substance use behaviors and disorders among adult sexual minorities by age, gender, and sexual identity. Drug Alcohol Depend. 2018; 189: 139 ‐ 146.
dc.identifier.citedreferenceKecojevic A, Wong CF, Schrager SM, et al. Initiation into prescription drug misuse: differences between lesbian, gay, bisexual, transgender (LGBT) and heterosexual high‐risk young adults in Los Angeles and New York. Addict Behav. 2012; 37 ( 11 ): 1289 ‐ 1293.
dc.identifier.citedreferenceSkinner WF. The prevalence and demographic predictors of illicit and licit drug use among lesbians and gay men. Am J Public Health. 1994; 84 ( 8 ): 1307 ‐ 1310.
dc.identifier.citedreferenceCochran SD, Ackerman D, Mays VM, et al. Prevalence of non‐medical drug use and dependence among homosexually active men and women in the US population. Addiction. 2004; 99 ( 8 ): 989 ‐ 998.
dc.identifier.citedreferenceMazure CM. Our evolving science: studying the influence of sex in preclinical research. Biol Sex Differ. 2016; 7 ( 1 ): 15. https://doi.org/10.1186/s13293‐016‐0068‐8
dc.identifier.citedreferenceMacLean RR, Armstrong JL, Sofuoglu M. Stress and opioid use disorder: a systematic review. Addict Behav. 2019; 98: 106010. https://doi.org/10.1016/j.addbeh.2019.05.034
dc.identifier.citedreferenceMcHugh RK, Kneeland ET, Edwards RE, et al. Pain catastrophizing and distress intolerance: prediction of pain and emotional stress reactivity. J Behav Med. 2020; 43: 623 ‐ 629.
dc.identifier.citedreferenceMoran LM, Kowalczyk WJ, Phillips KA, et al. Sex differences in daily life stress and craving in opioid‐dependent patients. Am J Drug Alcohol Abuse. 2018; 44 ( 5 ): 512 ‐ 523.
dc.identifier.citedreferenceRoos CR, Kiluk BD, McHugh RK, et al. Evaluating a longitudinal mediation model of perceived stress, depressive symptoms, and substance use treatment. Psychol Addict Beh. 2020; 34 ( 6 ): 660 ‐ 668.
dc.identifier.citedreferenceVolkow ND, Frieden TR, Hyde PS, et al. Medication‐assisted therapies—tackling the opioid‐overdose epidemic. NEJM. 2014; 370 ( 22 ): 2063 ‐ 2066.
dc.identifier.citedreferenceAlderks CE. Trends in the Use of Methadone, Buprenorphine, and Extended‐Release Naltrexone at Substance Abuse Treatment Facilities: 2003–2015 (update). The CBHSQ Report. Substance Abuse and Mental Health Services Administration (U.S.); 2017. https://www.samhsa.gov/data/sites/default/files/report_3192/ShortReport‐3192.html. Accessed July 28, 2020
dc.identifier.citedreferenceKolodny A, Frieden TR. Ten steps the federal government should take now to reverse the opioid addiction epidemic. JAMA. 2017; 318 ( 16 ): 1537 ‐ 1538.
dc.identifier.citedreferenceSoelberg CD, Brown RE, Du Vivier D, et al. The U.S. opioid crisis: current federal and state legal issues. Anesth Analg. 2017; 125 ( 5 ): 1675 ‐ 1681.
dc.identifier.citedreferenceTetrault JM, Fiellin DA. More beds or more chairs? Using a science‐based approach to address the opioid epidemic. Ann Intern Med. 2018; 168 ( 1 ): 73 ‐ 74.
dc.identifier.citedreferenceLagisetty PA, Ross R, Bohnert A, et al. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019; 76 ( 9 ): 979 ‐ 981.
dc.identifier.citedreferencePanchal N, Kamal R, Orgera K, et al. The Implications of COVID‐19 for Mental Health and Substance Use. Kaiser Family Foundation. https://www.kff.org/health‐reform/issue‐brief/the‐implications‐of‐covid‐19‐for‐mental‐health‐and‐substance‐use/. Accessed July 28, 2020
dc.identifier.citedreferenceMcGinty EE, Presskreischer R, Han H, et al. Psychological distress and loneliness reported by U.S. adults in 2018 and April 2020. JAMA. 2020; 324 ( 1 ): 93 ‐ 94.
dc.identifier.citedreferenceNational Academy of Medicine. Priorities and strategies to preserve the health and well‐being of individuals with substance use disorders and chronic pain during COVID‐19. https://nam.edu/programs/action‐collaborative‐on‐countering‐the‐u‐s‐opioid‐epidemic/covid‐19‐statement‐of‐priorities‐page/. Accessed July 28, 2020
dc.identifier.citedreferenceNational Academy of Medicine. Resources on Addiction and Pain Management Services During COVID‐19. https://nam.edu/programs/action‐collaborative‐on‐countering‐the‐u‐s‐opioid‐epidemic/resources‐on‐addiction‐and‐pain‐management‐services‐during‐covid‐19. Accessed July 28, 2020
dc.identifier.citedreferenceMazure CM, Fiellin DA. Women and opioids: something different is happening here. Lancet (London, England). 2018; 392: 9 ‐ 11.
dc.identifier.citedreferenceFloyd CN, Warren JB. Opioids out of control. Br J Clin Pharmacol. 2018; 84: 813 ‐ 815.
dc.identifier.citedreferenceKandall SR. Women and Addiction in the United States – 1850‐1920. In: Wetherington CL, Roman AB, eds. Drug Abuse Research and the Health of Women. National Institute on Drug Abuse. NIH Publication No. 98‐4290, 1998: 33 ‐ 52.
dc.identifier.citedreferenceKandall SR. Women and drug addiction: a historical perspective. J Addictive Dis. 2010; 29: 117 ‐ 126.
dc.identifier.citedreferenceKandall SR. Women and addiction in the United States – 1920 to the present. In: Wetherington CL, Roman AB, eds. Drug Abuse Research and the Health of Women. National Institute on Drug Abuse. NIH Publication No. 98‐4290, 1998: 53 ‐ 79.
dc.identifier.citedreferenceHumphreys K. Avoiding globalisation of the prescription opioid epidemic. Lancet (London, England). 2017; 390: 437 ‐ 439.
dc.identifier.citedreferenceDale R, Stacey B. Multimodal treatment of chronic pain. Med Clin. 2016; 100 ( 1 ): 55 ‐ 64.
dc.identifier.citedreferenceBecker WC, Fiellin DA. Limited evidence, faulty reasoning, and potential for a global opioid crisis. BMJ. 2017; 358: j3115.
dc.identifier.citedreferenceGuy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR. 2017; 66 ( 26 ): 697 ‐ 704.
dc.identifier.citedreferenceCiccarone D. Fentanyl in the U.S. heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017; 46: 107 ‐ 111.
dc.identifier.citedreferenceRose ME. Are prescription opioids driving the opioid crisis? Assumptions vs facts. Pain Med. 2018; 19 ( 4 ): 793 ‐ 807.
dc.identifier.citedreferenceHedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief. 2017; 294: 1 ‐ 8.
dc.identifier.citedreferenceCicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Beh. 2017; 74: 63 ‐ 66.
dc.identifier.citedreferenceGiovino GA. Epidemiology of tobacco use in the United States. Oncogene. 2002; 21 ( 48 ): 7326 ‐ 7340.
dc.identifier.citedreferenceGrant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM‐5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III. JAMA Psychiatry. 2015; 72 ( 8 ): 757 ‐ 766.
dc.identifier.citedreferenceMarsh JC, Park K, Lin Y‐A, et al. Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007–2014. J Subst Abuse Treat. 2018; 87: 79 ‐ 85.
dc.identifier.citedreferenceWetherington CL. Sex‐gender differences in drug abuse: a shift in the burden of proof? Exp Clin Psychopharmacol. 2007; 15 ( 5 ): 411 ‐ 417.
dc.identifier.citedreferenceGreenfield SF, Brooks AJ, Gordon SM, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007; 86 ( 1 ): 1 ‐ 21.
dc.identifier.citedreferenceMcKee SA, Smith PH, Kaufman M, et al. Sex differences in varenicline efficacy for smoking cessation: a meta‐analysis. Nic Tob Res. 2016; 18 ( 5 ): 1002 ‐ 1011.
dc.identifier.citedreferenceAiles EC, Dawson AL, Lind JN, et al. Opioid prescription claims among women of reproductive age—United States, 2008–2012. MMWR. 2015; 64 ( 2 ): 37 ‐ 41.
dc.identifier.citedreferenceAlexander MJ, Kiang MV, Barbieri M. Trends in black and white opioid mortality in the United States, 1979–2015. Epidemiology. 2018; 29 ( 5 ): 707 ‐ 715.
dc.identifier.citedreferenceHarrison JM, Lagisetty P, Sites BD, et al. Trends in prescription pain medication use by race/ethnicity among US adults with noncancer pain, 2000–2015. Am J Public Health. 2018; 108 ( 6 ): 788 ‐ 790.
dc.identifier.citedreferenceNicholson HL, Ford JA. Correlates of prescription opioid misuse among Black adults: findings from the 2015 National Survey on Drug Use and Health. Drug Alcohol Depend. 2018; 186: 264 ‐ 267.
dc.identifier.citedreferenceNicholson HL, Vincent J. Gender differences in prescription opioid misuse among US Black adults. Subst Use Misuse. 2019; 54 ( 4 ): 639 ‐ 650.
dc.identifier.citedreferenceZelaya CE, Dahlhamer JM, Lucas JW, Connor EM. Chronic Pain and High‐Impact Chronic Pain among U.S. Adults, 2019 NCHS Data Brief. Hyattsville, MD: National Center for Health Statistics. 2020; 390: 1 ‐ 7.
dc.identifier.citedreferenceCicero TJ, Wong G, Tian Y, et al. Co‐morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database. Pain. 2009; 144 ( 1–2 ): 20 ‐ 27.
dc.identifier.citedreferenceHirschtritt ME, Delucchi KL, Olfson M. Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993–2014. Prev Med Rep. 2018; 9: 49 ‐ 54.
dc.identifier.citedreferenceHwang CS, Kang EM, Kornegay CJ, et al. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002–2014. Am J Prev Med. 2016; 51 ( 2 ): 151 ‐ 160.
dc.identifier.citedreferenceNational Institute on Drug Abuse. January 2020. https://www.drugabuse.gov/drug‐topics/trends‐statistics/overdose‐death‐rates (accessed September 6, 2020).
dc.identifier.citedreferenceMiller TR, Swedler DI, Lawrence BA, et al. Incidence and lethality of suicidal overdoses by drug class. JAMA Netw Open. 2020; 3 ( 3 ): e200607.
dc.identifier.citedreferenceAshrafioun L, Bishop TM, Conner KR, Pigeon WR. Frequency of prescription opioid misuse and suicidal ideation, planning, and attempts. J Psychiatr Res. 2017; 92: 1 ‐ 7.
dc.identifier.citedreferenceSumner SA, Mercado‐Crespo MC, Spelke MB, et al. Use of naloxone by emergency medical services during opioid drug overdose resuscitation efforts. Prehosp Emerg Care. 2016; 20 ( 2 ): 220 ‐ 225.
dc.identifier.citedreferenceChristie C, Baker C, Cooper R, et al. The President’s Commission on Combating Drug Addiction and the Opioid Crisis. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11‐1‐2017.pdf. Accessed July 28, 2020
dc.identifier.citedreferenceBecker JB, Mazure CM. The federal plan for health science and technology’s response to the opioid crisis: understanding sex and gender differences as part of the solution is overlooked. Biol Sex Differ. 2019; 10 ( 1 ): 1 ‐ 3.
dc.identifier.citedreferencePardue M‐L, Wizemann TM. Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington DC: National Academies Press; 2001.
dc.identifier.citedreferenceFausto‐Sterling A. Sex/Gender: Biology in a Social World. New York: Routledge; 2012.
dc.identifier.citedreferenceFillingim RB, King CD, Ribeiro‐Dasilva MC, et al. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009; 10 ( 5 ): 447 ‐ 485.
dc.identifier.citedreferenceDahlhamer J, Lucas J, Zelaya C. Prevalence of chronic pain and high‐impact chronic pain among adults – United States, 2016. MMWR. 2018; 67 ( 36 ): 1001 ‐ 1006.
dc.identifier.citedreferenceMeints SM, Wang V, Edwards RR. Sex and race differences in pain sentization among patients with chronic low back pain. J Pain. 2018; 19 ( 12 ): 1461 ‐ 1470.
dc.identifier.citedreferenceNdao‐Brumblay SK, Green CR. Racial differences in the physical and psychosocial health among black and white women with chronic pain. J Natl Med Assoc. 2005; 97 ( 10 ): 1369 ‐ 1377.
dc.identifier.citedreferenceGreen CR, Baker TA, Sato Y, et al. Race and chronic pain: a comparative study of young black and white Americans presenting for management. J Pain. 2003; 4 ( 4 ): 176 ‐ 183.
dc.identifier.citedreferenceFuentes M, Hart‐Johnson T, Green CR. The association among neighborhood socioeconomic status, race and chronic pain in black and white older adults. J Natl Med Assoc. 2007; 99 ( 10 ): 1160 ‐ 1169.
dc.identifier.citedreferenceSorge RE, Totsch SK. Sex differences in pain. J Neurosci Res. 2017; 95: 1271 ‐ 1281.
dc.identifier.citedreferenceAveritt DL, Eidson LN, Doyle HH, Murphy AZ. Neuronal and glial factors contributing to sex differences in opioid modulation of pain. Neuropsychopharmacol. 2019; 44: 155 ‐ 165.
dc.identifier.citedreferenceWager TD, Scott DJ, Zubieta JK. Placebo effects on human mu‐opioid activity during pain. Proc Natl Acad Sci USA. 2007; 104: 11056 ‐ 11061.
dc.identifier.citedreferenceDoyle HH, Eidson LN, Sinkiewicz DM, Murphy AZ. Sex Differences in Microglia activity within the periaqueductal gray of the rat: a potential mechanism driving the dimorphic effects of morphine. J Neurosci. 2017; 37: 3202 ‐ 3214.
dc.identifier.citedreferenceMogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci. 2012; 13: 859 ‐ 866.
dc.identifier.citedreferenceSorge RE, Mapplebeck JCS, Rosen S, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci. 2015; 18: 1081 ‐ 1083.
dc.identifier.citedreferenceYu X, Liu H, Hamel KA, et al. Dorsal root ganglion macrophages contribute to both the initiation and persistence of neuropathic pain. Nat Commun. 2020; 11: 264.
dc.identifier.citedreferenceSorge RE, Martin LJ, Isbester KA, et al. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods. 2014; 11: 629 ‐ 632.
dc.identifier.citedreferenceHales CM, Martin CB, Gu Q. Prevalence of Prescription Pain Medication Use Among Adults: United States, 2015–2018. NCHS Date Brief Number 36; 2020.
dc.identifier.citedreferenceLevy B, Paulozzi L, Mack KA, et al. Trends in opioid analgesic–prescribing rates by specialty, US, 2007–2012. Am J Prev Med. 2015; 49 ( 3 ): 409 ‐ 413.
dc.identifier.citedreferenceNelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA. 2012; 308 ( 5 ): 457 ‐ 458.
dc.identifier.citedreferenceSchieber LZ. Variation in adult outpatient opioid prescription dispensing by age and sex—United States, 2008–2018. MMWR Morb Mortal Wkly Rep. 2020; 69 ( 11 ): 298 ‐ 302.
dc.identifier.citedreferenceCicero TJ, Ellis MS, Surratt HL, et al. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014; 71 ( 7 ): 821 ‐ 826.
dc.identifier.citedreferencePeterson AB, Gladden RM, Delcher C, et al. Increases in fentanyl‐related overdose deaths—Florida and Ohio, 2013–2015. MMWR. 2016; 65 ( 33 ): 844 ‐ 849.
dc.identifier.citedreferenceAlgren DA, Monteilh CP, Punja M, et al. Fentanyl‐associated fatalities among illicit drug users in Wayne County, Michigan (July 2005–May 2006). J Med Toxicol. 2013; 9 ( 1 ): 106 ‐ 115.
dc.identifier.citedreferenceBecker JB, Chartoff E. Sex differences in neural mechanisms mediating reward and addiction. Neuropsychopharmacol. 2019; 44: 166 ‐ 183.
dc.identifier.citedreferenceBecker JB, Koob GF. Sex differences in animal models: focus on addiction. Pharmacol Rev. 2016; 68: 242 ‐ 263.
dc.identifier.citedreferenceBecker JB, McClellan M, Reed BG. Sociocultural context for sex differences in addiction. Addict Biol. 2016; 21: 1052 ‐ 1059.
dc.identifier.citedreferenceKuhn C. Emergence of sex differences in the development of substance use and abuse during adolescence. Pharmacol Ther. 2015; 153: 55 ‐ 78.
dc.identifier.citedreferenceLynch WJ, Carroll ME. Sex differences in the acquisition of intravenously self‐administered cocaine and heroin in rats. Psychopharmacol. 1999; 144: 77 ‐ 82.
dc.identifier.citedreferenceCarroll ME, Morgan AD, Lynch WJ, Campbell UC, Dess NK. Intravenous cocaine and heroin self‐administration in rats selectively bred for differential saccharin intake: phenotype and sex differences. Psychopharmacol. 2002; 161: 304 ‐ 313.
dc.identifier.citedreferenceRoth ME, Casimir AG, Carroll ME. Influence of estrogen in the acquisition of intravenously self‐administered heroin in female rats. Pharmacol Biochem Behav. 2002; 72: 313 ‐ 318.
dc.identifier.citedreferenceTownsend EA, Negus SS, Caine SB, Thomsen M, Banks ML. Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats. Neuropsychopharmacol. 2019; 44: 2022 ‐ 2029.
dc.identifier.citedreferenceHutcheson DM, Parkinson JA, Robbins TW, Everitt BJ. The effects of nucleus accumbens core and shell lesions on intravenous heroin self‐administration and the acquisition of drug‐seeking behaviour under a second‐order schedule of heroin reinforcement. Psychopharmacol. 2001; 153: 464 ‐ 472.
dc.identifier.citedreferenceYoest KE, Cummings JA, Becker JB. Oestradiol influences on dopamine release from the nucleus accumbens shell: sex differences and the role of selective oestradiol receptor subtypes. Br J Pharmacol. 2019; 176: 4136 ‐ 4148.
dc.identifier.citedreferenceYoest KE, Quigley JA, Becker JB. Rapid effects of ovarian hormones in dorsal striatum and nucleus accumbens. Horm Behav. 2018; 104: 119 ‐ 129.
dc.identifier.citedreferenceCenter for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, detailed tables. Rockville, MD: SAMHSA Administration; 2018: 948 ‐ 949.
dc.identifier.citedreferenceBack SE, Payne RL, Simpson AN, et al. Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav. 2010; 35 ( 11 ): 1001 ‐ 1007.
dc.identifier.citedreferenceScambler G. Health‐related stigma. Sociol Health Illn. 2009; 31 ( 3 ): 441 ‐ 455.
dc.identifier.citedreferenceBawor M, Dennis BB, Varenbut M, et al. Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biol Sex Differ. 2015; 6 ( 1 ): 21. https://doi.org/10.1186/s13293‐015‐0038‐6
dc.identifier.citedreferenceBack SE, Payne RL, Wahlquist AH, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011; 37 ( 5 ): 313 ‐ 323.
dc.identifier.citedreferenceMcHugh RK, DeVito EE, Dodd D, et al. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abuse Treat. 2013; 45 ( 1 ): 38 ‐ 43.
dc.identifier.citedreferencePallatino C, Chang JC, Krans EE. The intersection of intimate partner violence and substance use among women with opioid use disorder. Subst Abuse. 2019; 1 ‐ 8.
dc.identifier.citedreferenceFalletta L, Hamilton K, Fischbein R, et al. Perceptions of child protective services among pregnant or recently pregnant, opioid‐using women in substance abuse treatment. Child Abuse Negl. 2018; 79: 125 ‐ 135.
dc.identifier.citedreferenceMeyer JP, Isaacs K, El‐Shahawy O, et al. Research on women with substance use disorders: reviewing progress and developing a research and implementation roadmap. Drug Alcohol Depend. 2019; 197: 158 ‐ 163.
dc.identifier.citedreferenceGuttmacher Institute. Substance Use During Pregnancy. https://www.guttmacher.org/state‐policy/explore/substance‐use‐during‐pregnancy. Accessed July 28, 2020
dc.identifier.citedreferenceNiv N, Hser Y‐I. Women‐only and mixed‐gender drug abuse treatment programs: service needs, utilization and outcomes. Drug Alcohol Depend. 2007; 87 ( 2–3 ): 194 ‐ 201.
dc.identifier.citedreferenceMcHugh RK, Votaw VR, Sugarman DE, et al. Sex and gender differences in substance use disorders. Clin Psychol Rev. 2018; 66: 12 ‐ 23.
dc.identifier.citedreferenceNational Academies of Sciences Engineering Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: National Academies Press; 2019. https://doi.org/10.17226/25310.
dc.identifier.citedreferenceLing S, Mangaoil R, Cleverley K, et al. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions. Drug Alcohol Depend. 2019; 197: 168 ‐ 182.
dc.identifier.citedreferenceManhapra A, Rosenheck R, Fiellin DA. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ. 2017;( 357 ): j1947.
dc.identifier.citedreferenceMoore BA, Fiellin DA, Cutter CJ, et al. Cognitive behavioral therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment. J Subst Abuse Treat. 2016; 71: 54 ‐ 57.
dc.identifier.citedreferenceJones ES, Fiellin DA. Women and opioid dependence treatment: office‐based versus opioid treatment program‐based care? Subst Abuse. 2007; 28 ( 2 ): 3 ‐ 8.
dc.identifier.citedreferenceBartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Brit J Amaesthes. 2013; 111 ( 1 ): 52 ‐ 59.
dc.identifier.citedreferenceMartin CE, Longinaker N, Terplan M. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J Subst Abuse Treat. 2015; 48 ( 1 ): 37 ‐ 42.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Healthcare Cost and Utilization Project. https://www.cdc.gov/pregnancy/opioids/data.html. Accessed July 29, 2020
dc.identifier.citedreferenceZedler BK, Mann AL, Kim MM, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐analysis of safety in the mother, fetus and child. Addiction. 2016; 111 ( 12 ): 2115 ‐ 2128.
dc.identifier.citedreferenceDebelak K, Morrone WR, O’Grady KE, et al. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. Am J Addict. 2013; 22 ( 3 ): 252 ‐ 254.
dc.identifier.citedreferenceJohnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003; 70 ( 2 ): S87 ‐ S101.
dc.identifier.citedreferenceJones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid‐dependent pregnant women: a comprehensive review. Addiction. 2012; 107: 5 ‐ 27.
dc.identifier.citedreferenceJones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. NEJM. 2010; 363 ( 24 ): 2320 ‐ 2331.
dc.identifier.citedreferenceJohnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid‐dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001; 63 ( 1 ): 97 ‐ 103.
dc.identifier.citedreferenceJones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid‐dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005; 79 ( 1 ): 1 ‐ 10.
dc.identifier.citedreferenceJones HE, O’Grady KE, Malfi D, et al. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008; 17 ( 5 ): 372 ‐ 386.
dc.working.doi10.7302/113en
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
fsb221303.pdf
Size:
128.7KB
Format:
PDF
View/Open
Name:
fsb221303_am.pdf
Size:
295.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.